[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371219-105":59,"doc-detail-371219-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","in-vitro-evaluation-of-the-safety-and-efficacy-of-cibisatamab-using-adult-stem-cell-derived-organoids-and-colorectal-cancer-spheroids","In Vitro Evaluation of the Safety and Efficacy of Cibisatamab Using Adult Stem Cell-Derived Organoids and Colorectal Cancer Spheroids","","Developing ex vivo systems that faithfully reproduce immune–tumor interactions is critical for advancing immunotherapy, because conventional two-dimensional in vitro models often lack the required complexity. This study establishes a comprehensive 3D redirect lysis assay combining colorectal cancer spheroids with adult stem cell-derived, healthy human organoids. The workflow integrates live imaging, cytotoxicity readouts, standardized effector-to-target ratios, and flow cytometry with Granzyme B release profiling. Results show dose-dependent tumor targeting and off-tumor binding and killing in organoids with intermediate CEA levels, supporting improved preclinical safety and potency assessment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/in-vitro-evaluation-of-the-safety-and-efficacy-of-cibisatamab-using-adult-stem-cell-derived-organoids-and-colorectal-cancer-spheroids/371219/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/in-vitro-evaluation-of-the-safety-and-efficacy-of-cibisatamab-using-adult-stem-cell-derived-organoids-and-colorectal-cancer-spheroids/371219.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in immunotherapy research?","Question",{"text":112,"@type":113},"Traditional two-dimensional in vitro systems often fail to capture the complexity of immune–tumor interactions, limiting predictive value for immunotherapy development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the 3D redirect lysis (3DRDL) model constructed?",{"text":117,"@type":113},"The model combines colorectal cancer spheroids with adult stem cell-derived, healthy human organoids and uses standardized co-culture effector-to-target ratios.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes indicate efficacy and safety for Cibisatamab?",{"text":121,"@type":113},"Cibisatamab induces dose-dependent cell death in high-CEA cancer spheroids, while off-tumor binding and killing are evaluated in organoids with intermediate CEA levels, alongside immune activation markers and Granzyme B release.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371219,1790913771,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nIn Vitro Evaluation of the Safety and Efficacy of Cibisatamab Using Adult Stem Cell-Derived Organoids and Colorectal Cancer Spheroids  \nVictor Anstett 1,†, Elisa Heinzelmann 1,†, Francesco Piraino 1, Aline Roch 1, Antonius Chrisnandy 1,  \nMaxim Norkin 2, Virginie Garnier 1, Krisztian Homicsko 2, Sylke Hoehnel-Ka 1, * and Nathalie Brandenberg 1, *  \nAcademic Editor: Marzia Bruna Gariboldi  \nReceived: 29 November 2024  \nRevised: 5 January 2025  \nAccepted: 13 January 2025  \nPublished: 17 January 2025  \nCitation: Anstett, V.; Heinzelmann, E.; Piraino, F.; Roch, A.; Chrisnandy, A.; Norkin, M.; Garnier, V.; Homicsko, K.; Hoehnel-Ka, S.; Brandenberg, N. In Vitro Evaluation of the Safety and Efficacy of Cibisatamab Using Adult Stem Cell-Derived Organoids and Colorectal Cancer Spheroids. Cancers 2025, 17, 291. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cancers17020291](10.3390/cancers17020291)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Doppl SA, 1015 Lausanne, Switzerland; [victor.anstett@doppl.ch](victor.anstett@doppl.ch) (V.A.); [elisa.heinzelmann@doppl.ch](elisa.heinzelmann@doppl.ch) (E.H.); [francesco.piraino@doppl.ch](francesco.piraino@doppl.ch) (F.P.); aline.roch@doppl.ch (A.R.)  \n2 Department of Oncology, CHUV, 1066 Lausanne, Switzerland; maxim.norkin@chuv.ch (M.N.);  \nkrisztian.homicsko@chuv.ch (K.H.)  \n* Correspondence: [sylke@doppl.ch](sylke@doppl.ch) (S.H.-K.); [nathalie.brandenberg@doppl.ch](nathalie.brandenberg@doppl.ch) (N.B.)† These authors contributed equally to this work.  \nSimple Summary: This study introduces an advanced 3D assay using colorectal cancer spheroids and adult stem cell-derived, healthy human organoids to evaluate the efficacy and safety of Cibisatamab, a bispecific antibody targeting carcinoembryonic antigens (CEAs) on cancer cells and CD3 on T cells. Our approach integrates live imaging and cytotoxicity analysis with standardized workflows, providing precise and reproducible insights into therapeutic effects. The findings reveal that Cibisatamab effectively targets high-CEAexpressing cancer cells and is dose-dependent on target, off-tumor binding and killing on non-cancerous cells. By capturing complex tumor-immune interactions and variations in therapeutic responses, this model offers a valuable tool for advancing immunotherapy research and predicting potential safety liabilities in clinical trials.  \nAbstract: Objectives: Developing ex vivo models that replicate immune–tumor interactions with high fidelity is essential for advancing immunotherapy research, as traditional twodimensional in vitro systems often lack the complexity required to fully represent these interactions. Methods: In this study, we establish a comprehensive 3D redirect lysis (3DRDL) assay using colorectal cancer spheroids and adult stem cell-derived, healthy human organoids to evaluate the efficacy and safety profile of Cibisatamab, a bispecific antibody targeting carcinoembryonic antigens (CEAs) on cancer cells and CD3 on T cells. This model allows us to assess cytotoxic activity and immune responses, capturing variations in therapeutic response not observable in simpler systems. Our model integrates live imaging and cytotoxicity analyses to enable precise, real-time tracking of antibody effects on CEA-expressing tumor cells compared to healthy cells. Additionally, by standardizing effector-to-target cell ratios in each co-culture, we establish a reproducible workflow that enhances data accuracy and comparability across assays. Flow cytometry and Granzyme B release profiling further allow us to characterize immune cell activation, revealing distinct T cell activation markers and Granzyme B release patte","cbCailU16vtDSQSy","https://ap.wps.com/l/cbCailU16vtDSQSy","pdf",2375690,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusions\n# Keywords\n# 1. Introduction","[{\"question\":\"What problem does the study address in immunotherapy research?\",\"answer\":\"Traditional two-dimensional in vitro systems often fail to capture the complexity of immune–tumor interactions, limiting predictive value for immunotherapy development.\"},{\"question\":\"How is the 3D redirect lysis (3DRDL) model constructed?\",\"answer\":\"The model combines colorectal cancer spheroids with adult stem cell-derived, healthy human organoids and uses standardized co-culture effector-to-target ratios.\"},{\"question\":\"What outcomes indicate efficacy and safety for Cibisatamab?\",\"answer\":\"Cibisatamab induces dose-dependent cell death in high-CEA cancer spheroids, while off-tumor binding and killing are evaluated in organoids with intermediate CEA levels, alongside immune activation markers and Granzyme B release.\"}]","In Vitro Evaluation of the Safety and Efficacy of Cibisatamab Using Adult Stem Cell-Derived Organoids and Colorectal Cancer Spheroids | PDF",1790191546,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26db9531357580f19909e0a814551469.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e43e07c96fec411faf080cdce313878c.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebafa7921ac27fb9e71959629809f301.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8efa096b6117f16fc1f0edc69d1cfe9e.webp",980,1385]